Source Fact: Financial Supervisory Service Electronic Disclosure System (DART) / 2025-11-24
Disclosure Type: Notice of New Listing of Stock Futures and Options
💡 3-Second Summary
Following its corporate division and subsequent relisting on the KOSPI market on November 24, 2025, new contract months for stock futures and options based on Samsung Biologics as the underlying asset will be newly listed and open for trading on November 25, 2025.
📊 1. [Summary of Core Disclosure Content and Major Figures]
- Reason for Listing: Corporate division of Samsung Biologics Co., Ltd. and its subsequent relisting on the KOSPI market on November 24, 2025.
- Newly Listed Derivatives and Contract Months:
- Stock Futures: December 2025, January 2026, February 2026, March 2026, June 2026, and September 2026 contracts.
- Stock Options: December 2025, January 2026, February 2026, March 2026, June 2026, and September 2026 contracts.
- Trading Commencement Date: November 25, 2025 (Tuesday) – The next trading day following the KOSPI market relisting date.
- Last Trading Day: The second Thursday of each respective contract month.
- Order Quantity Limit: 1,000 contracts (Maintained identical to the previous institutional limit).
- Governing Regulations: Article 22, 27, 28, and 37 of the Derivatives Market Business Regulations, alongside Article 8, 11, 13, and 19 of the enforcement rules.
📈 2. [Expert View: What This Disclosure Means for Investors]
- Realignment of Derivatives Trading Lineup: This filing serves as an administrative announcement regarding the listing of new contract months for futures and options markets, triggered by the corporate division and relisting of Samsung Biologics. This structural adjustment aligns with capital market technical specifications rather than tracking operational metrics like sales or production output.
- Availability of Risk Management Tools: The introduction of these new contract months provides spot investors with a broad array of portfolio hedging mechanisms. The launch of derivatives trading does not alter the underlying fundamental quality of the company itself. Because the regulatory filing does not comment on specific performance fluctuations or financial drivers, investors should interpret this solely as a technical restoration of market infrastructure.
- Monitoring Market Liquidity: The order quantity limit remains capped at 1,000 contracts, indicating no drastic shifts in the institutional trading framework. However, since multiple contract months are being introduced simultaneously, investors are encouraged to remain mindful of the upcoming volume trends in the derivatives segment and their corresponding arbitrage dynamics with the spot market.
📝 Editor’s Comment (by K-STOCK Editor)
This regulatory filing from Samsung Biologics provides official documentation that the underlying contract months for the stock’s futures and options have been reset to match its corporate division and relisting timeline. In accordance with market regulations, standard derivatives trading resumes on November 25, the day following the spot relisting. Investors should distinguish this institutional infrastructure setup from core fundamental performance indicators, as it does not imply any immediate shifts in revenue or corporate earnings. It is advisable to treat this update purely as a functional modification of trading access while calmly observing the initial liquidity building process across the new contract months.
📢 Disclaimer and Source Information
Source: This content was newly structured and written based on official submission data from the Financial Supervisory Service Electronic Disclosure System (DART).
Investment Risk Notice: This content is provided solely for informational and linguistic reference purposes. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific stocks. All investment decisions and financial responsibilities rest entirely with the investor.
Contact: For compliance inquiries or copyright requests, please contact ksb220805@gmail.com.
🔥 Bulls vs Bears, drop your analysis in the comments!
